Pharma Gets Warm Spotlight At White House Event Showcasing J&J-Merck Collaboration
Biden Administration seeks to put its stamp on a new phase of the US government’s collaboration with the pharma industry against COVID-19.
You may also be interested in...
The story of the US coronavirus vaccine production ramp-up is putting the drug industry in an extraordinarily favorable public relations position. One downside, however, may be complicating the industry’s message about the limits of ‘Buy American’ efforts on pharmaceutical supply chains overall.
Conveniently omitting Germany’s BioNTech, the US president says ‘development, manufacture, and distribution of the vaccines in record time is a true miracle of science. It is one of the most extraordinary achievements any country has ever accomplished.’
Some manufacturers may have to start essentially paying Medicaid programs to cover their drugs beginning in 2024 under a provision in the US economic relief bill headed to President Biden.